Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 7/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.43 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22323840 | 1.00 | ZDHHC2 (0.50) | ZDHHC2EP300FAAHPPARASOAT2 | |
| SCHEMBL9781746 | 1.00 | ZDHHC2 (0.50) | ZDHHC2EP300FAAHPPARASOAT2 | |
| SCHEMBL22323843 | 1.00 | ZDHHC2 (0.50) | ZDHHC2EP300FAAHPPARASOAT2 | |
| SCHEMBL22323842 | 1.00 | ZDHHC2 (0.50) | ZDHHC2EP300FAAHPPARASOAT2 | |
| SCHEMBL22323852 | 0.98 | ZDHHC2 (0.48) | ZDHHC2EP300FAAHPPARASOAT2 | |
| SCHEMBL22323853 | 0.98 | ZDHHC2 (0.48) | ZDHHC2EP300FAAHPPARASOAT2 | |
| SCHEMBL22323850 | 0.87 | ZDHHC2 (0.41) | ZDHHC2FAAH | |
| SCHEMBL22323848 | 0.87 | ZDHHC2 (0.41) | ZDHHC2FAAH | |
| SCHEMBL4218119 | 0.87 | ZDHHC2 (0.41) | ZDHHC2FAAH | |
| SCHEMBL2831627 | 0.86 | ZDHHC2 (0.46) | ZDHHC2EP300FAAHPPARASOAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177227-B1 | WATER PLASTICIZED HIGH REFRACTIVE INDEX POLYMER FOR OPHTHALMIC APPLICATIONS | SURGIDEV CORP (US) | 2003-10-01 | — | — | EP | claimed |
| US-11931365-B2 | Use of PPAR-delta agonists in the treatment of disease | RENEO PHARMACEUTICALS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240016809-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | RENEO PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| WO-2023147309-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | RENEO PHARMACEUTICALS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230233570-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | RENEO PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | WASHINGTON UNIVERSITY | 2022-11-24 | — | — | US | disclosed |
| EP-4031124-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | Reneo Pharmaceuticals, Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| CN-114727976-A | Use of PPAR-delta agonists in the treatment of renal disease | 雷内奥制药公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | RENEO PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | RENEO PHARMACEUTICALS, INC. | 2022-01-27 | — | — | US | disclosed |
| EP-3927718-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | Reneo Pharmaceuticals, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3920903-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | Reneo Pharmaceuticals, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| CN-113747891-A | Use of PPAR delta agonists in the treatment of Fatty Acid Oxidation Disorders (FAOD) | 雷内奥制药公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-113710683-A | Use of PPAR-delta agonists in the treatment of mitochondrial myopathy | 雷内奥制药公司 | 2021-11-26 | — | — | CN | disclosed |
| WO-2021055725-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | RENEO PHARMACEUTICALS, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2020163240-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | RENEO PHARMACEUTICALS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | PPARG, PPARA, PPARD | ZDHHC2 749/4885EP300 247/4885FAAH 416/4885 |
| US-11931365-B2 | Use of PPAR-delta agonists in the treatment of disease | PPARG, PPARD, PPARA | ZDHHC2 434/4885EP300 152/4885FAAH 748/4885 |
| US-20230233570-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | PPARG, PPARD, PPARA | ZDHHC2 434/4885EP300 152/4885FAAH 748/4885 |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | PPARD, PPARA, MTPN | ZDHHC2 831/4885EP300 1686/4885FAAH 1062/4885 |
| US-20240016809-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | PPARG, PPARD, PPARA | ZDHHC2 434/4885EP300 152/4885FAAH 748/4885 |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | PPARD, ACOX1, CPT1A | ZDHHC2 212/4885EP300 936/4885FAAH 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.